Aventis/TKT Dynepo Regulatory Review Commences, Patent Suit Continues
Executive Summary
The regulatory pathway of gene-activated erythropoietin Dynepo is evidence that the product is not equivalent to Amgen's Epogen, Aventis Chief Scientific Officer Frank Douglas, MD/PhD, said July 18 in Boston federal court.
You may also be interested in...
NORD Intervention In EPO Appeal Seeks Consideration Of Amgen Epogen Cost
The National Organization for Rare Disorders is attempting to have the issue of drug pricing play a role in the appeal of the erythropoietin patent case Amgen v. Aventis/Transkaryotic Therapies.
NORD Intervention In EPO Appeal Seeks Consideration Of Amgen Epogen Cost
The National Organization for Rare Disorders is attempting to have the issue of drug pricing play a role in the appeal of the erythropoietin patent case Amgen v. Aventis/Transkaryotic Therapies.
Aventis Builds U.S. Diabetes Portfolio On Strong Amaryl Performance
Aventis is building its U.S. diabetes franchise in the near term based on strong sales of the oral sulfonylurea Amaryl, Investor Relations Director Arvind Sood said during a conference call July 28.